143 related articles for article (PubMed ID: 9043664)
1. Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex.
Taveras AG; Remiszewski SW; Doll RJ; Cesarz D; Huang EC; Kirschmeier P; Pramanik BN; Snow ME; Wang YS; del Rosario JD; Vibulbhan B; Bauer BB; Brown JE; Carr D; Catino J; Evans CA; Girijavallabhan V; Heimark L; James L; Liberles S; Nash C; Perkins L; Senior MM; Tsarbopoulos A; Webber SE
Bioorg Med Chem; 1997 Jan; 5(1):125-33. PubMed ID: 9043664
[TBL] [Abstract][Full Text] [Related]
2. Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange.
Burns MC; Sun Q; Daniels RN; Camper D; Kennedy JP; Phan J; Olejniczak ET; Lee T; Waterson AG; Rossanese OW; Fesik SW
Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3401-6. PubMed ID: 24550516
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
[TBL] [Abstract][Full Text] [Related]
4. KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry.
Lu J; Harrison RA; Li L; Zeng M; Gondi S; Scott D; Gray NS; Engen JR; Westover KD
Structure; 2017 Sep; 25(9):1442-1448.e3. PubMed ID: 28781083
[TBL] [Abstract][Full Text] [Related]
5. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
[TBL] [Abstract][Full Text] [Related]
6. Structural Biology-Inspired Discovery of Novel KRAS-PDEδ Inhibitors.
Jiang Y; Zhuang C; Chen L; Lu J; Dong G; Miao Z; Zhang W; Li J; Sheng C
J Med Chem; 2017 Nov; 60(22):9400-9406. PubMed ID: 28929751
[TBL] [Abstract][Full Text] [Related]
7. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design.
Ostrem JM; Shokat KM
Nat Rev Drug Discov; 2016 Nov; 15(11):771-785. PubMed ID: 27469033
[TBL] [Abstract][Full Text] [Related]
8. Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation.
Winter JJ; Anderson M; Blades K; Brassington C; Breeze AL; Chresta C; Embrey K; Fairley G; Faulder P; Finlay MR; Kettle JG; Nowak T; Overman R; Patel SJ; Perkins P; Spadola L; Tart J; Tucker JA; Wrigley G
J Med Chem; 2015 Mar; 58(5):2265-74. PubMed ID: 25695162
[TBL] [Abstract][Full Text] [Related]
9. Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D).
Palmioli A; Sacco E; Airoldi C; Di Nicolantonio F; D'Urzo A; Shirasawa S; Sasazuki T; Di Domizio A; De Gioia L; Martegani E; Bardelli A; Peri F; Vanoni M
Biochem Biophys Res Commun; 2009 Sep; 386(4):593-7. PubMed ID: 19540195
[TBL] [Abstract][Full Text] [Related]
10. Regional polysterism in the GTP-bound form of the human c-Ha-Ras protein.
Ito Y; Yamasaki K; Iwahara J; Terada T; Kamiya A; Shirouzu M; Muto Y; Kawai G; Yokoyama S; Laue ED; Wälchli M; Shibata T; Nishimura S; Miyazawa T
Biochemistry; 1997 Jul; 36(30):9109-19. PubMed ID: 9230043
[TBL] [Abstract][Full Text] [Related]
11.
Quah SY; Tan MS; Ho KL; Manan NA; Gorfe AA; Deb PK; Sagineedu SR; Stanslas J
Future Med Chem; 2020 Sep; 12(18):1611-1631. PubMed ID: 32892640
[No Abstract] [Full Text] [Related]
12. Second harmonic generation detection of Ras conformational changes and discovery of a small molecule binder.
Donohue E; Khorsand S; Mercado G; Varney KM; Wilder PT; Yu W; MacKerell AD; Alexander P; Van QN; Moree B; Stephen AG; Weber DJ; Salafsky J; McCormick F
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17290-17297. PubMed ID: 31399543
[TBL] [Abstract][Full Text] [Related]
13. Dynamic studies of H-Ras•GTPγS interactions with nucleotide exchange factor Sos reveal a transient ternary complex formation in solution.
Vo U; Vajpai N; Embrey KJ; Golovanov AP
Sci Rep; 2016 Jul; 6():29706. PubMed ID: 27412770
[TBL] [Abstract][Full Text] [Related]
14. The RAS-Binding Domain of Human BRAF Protein Serine/Threonine Kinase Exhibits Allosteric Conformational Changes upon Binding HRAS.
Aramini JM; Vorobiev SM; Tuberty LM; Janjua H; Campbell ET; Seetharaman J; Su M; Huang YJ; Acton TB; Xiao R; Tong L; Montelione GT
Structure; 2015 Aug; 23(8):1382-1393. PubMed ID: 26165597
[TBL] [Abstract][Full Text] [Related]
15. Solution structure and dynamics of ras p21.GDP determined by heteronuclear three- and four-dimensional NMR spectroscopy.
Kraulis PJ; Domaille PJ; Campbell-Burk SL; Van Aken T; Laue ED
Biochemistry; 1994 Mar; 33(12):3515-31. PubMed ID: 8142349
[TBL] [Abstract][Full Text] [Related]
16. Multivalent Small-Molecule Pan-RAS Inhibitors.
Welsch ME; Kaplan A; Chambers JM; Stokes ME; Bos PH; Zask A; Zhang Y; Sanchez-Martin M; Badgley MA; Huang CS; Tran TH; Akkiraju H; Brown LM; Nandakumar R; Cremers S; Yang WS; Tong L; Olive KP; Ferrando A; Stockwell BR
Cell; 2017 Feb; 168(5):878-889.e29. PubMed ID: 28235199
[TBL] [Abstract][Full Text] [Related]
17. Molecular Basis for Allosteric Inhibition of GTP-Bound H-Ras Protein by a Small-Molecule Compound Carrying a Naphthalene Ring.
Matsumoto S; Hiraga T; Hayashi Y; Yoshikawa Y; Tsuda C; Araki M; Neya M; Shima F; Kataoka T
Biochemistry; 2018 Sep; 57(36):5350-5358. PubMed ID: 30141910
[TBL] [Abstract][Full Text] [Related]
18. Mapping the nucleotide-dependent conformational change of human N-ras p21 in solution by heteronuclear-edited proton-observed NMR methods.
Hu JS; Redfield AG
Biochemistry; 1993 Jul; 32(26):6763-72. PubMed ID: 8329399
[TBL] [Abstract][Full Text] [Related]
19. Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP.
Geyer M; Schweins T; Herrmann C; Prisner T; Wittinghofer A; Kalbitzer HR
Biochemistry; 1996 Aug; 35(32):10308-20. PubMed ID: 8756686
[TBL] [Abstract][Full Text] [Related]
20. Ras-15A protein shares highly similar dominant-negative biological properties with Ras-17N and forms a stable, guanine-nucleotide resistant complex with CDC25 exchange factor.
Chen SY; Huff SY; Lai CC; Der CJ; Powers S
Oncogene; 1994 Sep; 9(9):2691-8. PubMed ID: 8058333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
